Respiratory Trainee - interested in Immunology, Infectious Disease, Critical Care. Lover of festivals/music/art. ILD Fellow SCGH, Perth 2024 🇦🇺
Perth, Western Australia
Joined February 2013
- Tweets1.9K
- Following858
- Followers432
- Likes7.8K
GraceKa retweeted
This #Movember I am pleased to announce a major milestone towards our National Registry for #TesticularCancer #Survivors
#SLECT trial now approved by R&I in @stjamesdublin and @CancerInstIRE
Hoping to expand to other cancer centre in coming weeks
GraceKa retweeted
Approved today: the first ever approved therapy for bronchiectasis in Europe
Congratulations investigators, patients and Insmed
Science changes lives
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - Nov 18, 2025
investor.insmed.com/2025-11-…
GraceKa retweeted
Today I learned that sometimes hepatocellular carcinoma can be diagnosed on imaging alone. If the patient has cirrhosis, chronic hep B or prior HCC an LI-RADS score of 5 is diagnostic! LI-RADS 4 requires biopsy and LI-RADS 3 or less is likely benign and can be monitored.
GraceKa retweeted
A new paper published in The Lancet — one of the world's most respected health journals — finds that sanctions imposed by the West on developing countries have caused *38 million deaths* since 1971.
GraceKa retweeted
Does mental stress affect our mitochondria?
In this new paper, we asked if 5 minutes of mental stress (public speaking) changed the amount of cell-free mitochondrial DNA (cf-mtDNA)
Absolute saliva cf-mtDNA levels increased on average by 280% after mental stress!
🧵
GraceKa retweeted
Is this the end of rivaroxaban for acute VTE?
@LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months.
56% reduction in bleeding risk with apixaban.
A safer Rx with the same efficacy.
#ISTH2025
GraceKa retweeted
Great news! The CHORUS Trial is now open to recruitment, congratulations to @PilarRiveraOrt1 and her team for being the first site to open. @RoyalDevonNHS Excited to get started 🎉📷 @ActionPFcharity
GraceKa retweeted
ERJOR: A walk test of 3 min still detects most desaturation events with equivalent prognostic value. Shorter walk tests could be used clinically, which would be a more efficient and patient-centred approach and also help the move towards remote monitoring. bit.ly/43rebnv
GraceKa retweeted
Today, I spoke @NorthwesternMed Grand Rounds on “The Price of Progress” - a reminder our excitement post-#ASCO25 should be tempered by reality:
🧾 33% of pts spend their life savings within 2 yrs of a cancer dx
🧠 50% experience financial distress
💼 75% leave the workforce
GraceKa retweeted
Find all TAPS (The Australasian Pleural Seminars): 15min @ on
youtube.com/@TheAustralasian…
Or go straight to the latest from @e_fysh on Pleural Effusion in Intensive Care on
youtube.com/watch?v=XtFksPUU…
Enjoy!
@PleuralPOCUS @UKPleura @ALATorax @aabip @tsanz_thoracic @TOGAANZ @APSRapsr @accpchest @NCARD_research @uwanews @PulmPEEPs @iPulmOG
GraceKa retweeted
Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team nejm.org/doi/full/10.1056/NE…
GraceKa retweeted
Breathe: This review summarises interesting insights into interstitial lung disease pathogenesis from a translational science point of view @3Assembly @ERSpublications @EuroRespSoc @EarlyCareerERS @SaraOcana1 bit.ly/4iRjP8s
GraceKa retweeted
Clinical Statement: Medical management of inpatients with tobacco dependency. @BTSrespiratory @ThoraxBMJ thorax.bmj.com/content/79/Su… @AshOrgUK @asthmalunguk
GraceKa retweeted
ERJ: Pirfenidone does not significantly reduce the proportion of patients with post-COVID-19 fibrotic changes after 6 months of treatment. FVC % improvement and % HRCT fibrotic reduction with pirfenidone were not statistically different from placebo. bit.ly/4alhGid
GraceKa retweeted
Everyone in CTD-ILD world, please see this paper on Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD), a RCT in IIM-ILD. Even though primary outcome was not met, but PFTs and HRCT trends before and after Abatacept are interesting and worth considering further larger study. Congratulations to Attack My ILD team and especially Nantakarn. academic.oup.com/rheumatolog…
GraceKa retweeted
Serum IgG from pulmonary arterial hypertension (PAH) patients show specific reactivities against Annexin A5 (ANXA5) and other antigens not recognized by serum IgG from those without PAH. Anti-Annexin A5 (ANXA5) IgG autoantibodies are detected in one-third of systemic lupus erythematosus (SLE)-associated PAH patients and over two-thirds of mixed connective tissue disease (MCTD)-PAH patients. These findings indicate that anti-ANXA5 IgG antibody reactivity in patients with SLE and MCTD could potentially predict PAH occurrence during follow-up.
*Thoreau B, Renaud A, Chafey P, et al. Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD). Rheumatology (Oxford). 2025 Feb 7.
🔗doi.org/10.1093/rheumatology…
GraceKa retweeted
Eur Respir J: In the phase II AIRLEAF trial, conducted in 322 adults with bronchiectasis, treatment with BI 1291583 resulted in a reduction in the risk of experiencing an exacerbation. The safety profile of BI 1291583 was similar to that of placebo. bit.ly/4dFSQdX
